Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).

Authors

Mothaffar F. Rimawi

Baylor College of Medicine, Houston, TX

Mothaffar F. Rimawi , Christopher John Poole , Jean-Marc Ferrero , Juan R. De la Haba Rodriguez , Lada Mitchell , Christina H. Pelizon , Grazia Arpino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.

First Author: Nicholas Patrick McAndrew

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).

First Author: Gargi D. Basu

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).

First Author: Mario Campone

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.

First Author: Sayeh Moazami Lavasani